Infantile Inflammatory Myofibroblastic Tumor of Spleen

被引：3

作者：

Thirunavukkarasu, Balamurugan ^{[1
]}

Roy, Pritam Singha ^{[2
]}

Gupta, Kirti ^{[1
]}

Sekar, Aravind ^{[1
]}

Bansal, Deepak ^{[2
]}

机构：

[1] Post Grad Inst Med Educ & Res, Histopathol, 5th Floor,A Block,Sect 12, Chandigarh 160012, India

[2] Post Grad Inst Med Educ & Res, Pediat, Chandigarh, India

来源：

FETAL AND PEDIATRIC PATHOLOGY | 2022年 / 41卷 / 03期

关键词：

Inflammatory myofibroblastic tumor; ALK; Epstein– Barr virus; spleen; ROS1; EPSTEIN-BARR-VIRUS; ROS1; ALK; REARRANGEMENTS; PSEUDOTUMOR; EXPRESSION;

D O I：

10.1080/15513815.2020.1836098

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Background: Inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm with unknown etiology and recurrent potential. They are widely reported in children and young adults. Nearly 50% of inflammatory myofibroblastic tumor harbor rearrangement in anaplastic lymphoma kinase (ALK) gene with the majority expressing ALK protein. ALK-negative IMTs harbor alteration in ROS1 gene in a subset of cases. Few reports have shown association of IMT with Epstein-Barr virus (EBV). Case report: We report a case of IMT of the spleen in an 18-month-old infant presenting with abdominal distention and failure to thrive. Workup for ALK-1, ROS1, and EBV small-encoded RNA in-situ hybridization using immunohistochemistry was negative. Conclusions: IMT can arise in an infant spleen.

引用

页码：475 / 479

页数：5

共 16 条

[11] Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation
Ogata, Misato
Hatachi, Yukimasa
Ogata, Takatsugu
Satake, Hironaga
Imai, Yukihiro
Yasui, Hisateru
[J]. INTERNAL MEDICINE, 2019, 58 (07) : 1029 - 1032
[12] Detection of Epstein-Barr virus in an inflammatory myofibroblastic tumor of the spleen (inflammatory pseudotumor)
Palomeque Jimenez, Antonio
Reyes Morenoa, Montserrat
Calzado Baeza, Salvador
Ranea Jimena, Sergio A.
Robayo Soto, Paul Sebastian
[J]. CIRUGIA ESPANOLA, 2015, 93 (06): : E41 - E43
[13] IgG4 plasma cells in inflammatory myofibroblastic tumor: inflammatory marker or pathogenic link?
Saab, Shahrazadb T.
Hornick, Jason L.
Fletcher, Christopher D.
Olson, Sandra J.
Coffin, Cheryl M.
[J]. MODERN PATHOLOGY, 2011, 24 (04) : 606 - 612
[14] Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial
Schoffski, Patrick
Sufliarsky, Jozef
Gelderblom, Hans
Blay, Jean-Yves
Strauss, Sandra J.
Stacchiotti, Silvia
Rutkowski, Piotr
Lindner, Lars H.
Leahy, Michael G.
Italiano, Antoine
Isambert, Nicolas
Debiec-Rychter, Maria
Sciot, Raf
Van Cann, Thomas
Marreaud, Sandrine
Nzokirantevye, Axelle
Collette, Sandra
Wozniak, Agnieszka
[J]. LANCET RESPIRATORY MEDICINE, 2018, 6 (06) : 431 - 441
[15] Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7
[16] ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours
Yamamoto, Hidetaka
Yoshida, Akihiko
Taguchi, Kenichi
Kohashi, Kenichi
Hatanaka, Yui
Yamashita, Atsushi
Mori, Daisuke
Oda, Yoshinao
[J]. HISTOPATHOLOGY, 2016, 69 (01) : 72 - 83

← 1 2 →